Investors in Novo Nordisk Urged to Join Class Action Suit by Levi & Korsinsky

Class Action Lawsuit Against Novo Nordisk

Levi & Korsinsky, LLP has announced important information for investors of Novo Nordisk A/S, or "Novo," regarding a class action securities lawsuit currently underway. The deadline for affected investors to join the action is set for September 30, 2025. This opportunity arises from the allegation of securities fraud against the company, which purportedly occurred between May 7, 2025, and July 28, 2025.

Background of the Case

The crux of the lawsuit lies in the claim that defendants made overly optimistic statements to investors while simultaneously sharing misleading information about Novo’s real growth potential. Specifically, they are accused of downplaying the true impact of the personalization exception to compounded GLP-1s, a key segment in the weight management market.

The complaint alleges that Novo overstated its capacity to attract patients away from competitors and misrepresented the true size and potential of the GLP-1 market. On July 29, 2025, the company revealed a significant revision to its sales and profit forecasts for the latter half of 2025, attributing this to unrealistic growth expectations for its popular products, Wegovy and Ozempic.

Stock Market Response

Following this announcement, Novos’s stock price plummeted dramatically, dropping from $69.00 per share at the closing on July 28 to just $53.94 the following day, marking a staggering decline of 21.83% in less than 24 hours. This swift market reaction underscored the potential damage caused by the alleged misinformation provided by the company.

Investor Considerations

For those who sustained losses in Novo’s stock during the aforementioned period, the lawsuit offers a path for potential recovery. Interested investors have until September 30, 2025, to petition the court for lead plaintiff status, although participation in a recovery does not require this designation.

It's important to note that investors can join the suit without incurring any out-of-pocket costs, as Levi & Korsinsky operates on a contingency basis. This means that if the class does recover, legal fees will be taken from the settlement, rather than upfront payments by the investors.

The Expertise of Levi & Korsinsky

Levi & Korsinsky is well-established in the realm of securities litigation, having secured hundreds of millions of dollars for disgruntled shareholders over two decades. The firm combines a vast array of resources and experience, making it one of the top contenders in handling complex securities-related litigations in the United States. For several consecutive years, they have ranked high in ISS Securities Class Action Services’ reports, signifying their credibility in this legal field.

How to Get Involved

Investors looking to find out more about joining this class action can reach out to Joseph E. Levi, Esq. at Levi & Korsinsky via email at [email protected] or by phone at (212) 363-7500. The firm offers comprehensive assistance and guidance throughout the process.

In summary, those affected by the alleged actions of Novo Nordisk should consider this opportunity. Joining the class action may not only provide a chance for financial restitution but also emphasizes accountability in corporate governance and investor relations.

For more detailed information regarding this case and the registration process, visit this link. Stay informed and protect your rights as an investor in the face of potential securities fraud.